NorthStrive Biosciences Partnered With Charles River

The Newport Beach firm engaged the lab to characterize engineered probiotic candidates EL-22 and EL-32.

Updated on Sept. 29, 2026 in Life Sciences

NorthStrive Biosciences Partnered With Charles River

Live Poll

Do you trust pharmaceutical companies to safely develop and test new engineered biological health products?

NorthStrive Biosciences has executed a statement of work with Charles River Laboratories to conduct analytical characterization of its EL-22 and EL-32 probiotic candidates. The project aims to improve product identity and manufacturing consistency for the engineered bacterial therapies.

Why it matters

This collaboration supports NorthStrive’s efforts to advance its platform toward an IND-enabling development framework. The company intends for these engineered probiotics to assist in muscle preservation for patients currently using GLP-1 weight loss treatments.

Charles River Laboratories will utilize DNA isolation, nucleic-acid amplification, and fluorescent-probe technology to analyze plasmid copy numbers. This methodology quantifies genetic constructs to ensure precision within the bacterial product candidates.

The players

NorthStrive Biosciences

This biotechnology firm specializes in engineered probiotics and is a subsidiary of PMGC Holdings Inc.

Charles River Laboratories

This global contract research organization provides critical drug discovery and development support services.

The details

Testing will occur at Charles River’s U.S. Biologics Testing sites to ensure the stability of the engineered probiotics. NorthStrive Biosciences, a subsidiary of PMGC Holdings Inc., is headquartered in Newport Beach.

NorthStrive Biosciences executed the statement of work on September 29, 2026.

The Big Picture

This testing regimen aligns with the regulatory requirements mandated by the FDA IND-enabling development framework to ensure safety and consistency before human trials. The work bridges the gap between early-stage laboratory discovery and formal clinical testing protocols.

If successful, this development could eventually provide a non-pharmacological support tool for individuals managing muscle mass while on GLP-1 weight loss medications. The research remains in the preclinical characterization phase, meaning no direct consumer product is currently available.

The takeaway

Advancing engineered probiotics requires rigorous analytical validation of genetic constructs to ensure predictable biological activity. Patients and clinicians should monitor for future updates regarding the transition of these candidates into clinical-stage research.